drugset / Trial / NCT07150208
T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Bevicizumab in HER2-low breast cancer with brain metastasis.
Timeline
- Start
- 2025-09
- Primary completion
- 2027-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | — |